Alpha Cognition…announced that the European Patent Ofﬁce (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease

Zunveyl (benzgalantamine) - Alpha Cognition

Jul 29, 2026